drugset
drugset / Trial / NCT04785326

Efficacy, Safety, and Immunogenicity of Subcutaneous DMB-3115 Versus Stelara® in Patients With Moderate to Severe Chronic Plaque Psoriasis

NCT04785326 ↗

Phase 3 Completed 598 enrolled Dong-A ST Co., Ltd. Meiji Seika Pharma Co., Ltd. · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

This study is designed to evaluate efficacy, safety, pharmacokinetics (PK) and immunogenicity of subcutaneously administered DMB-3115 in comparison with Stelara for treatment of moderate to severe chronic plaque psoriasis.

Timeline

Start
2021-04-28
Primary completion
2022-02-10
Completion
2022-11-16

Drugs

EvaluationDrugModalityDoseRoute
Subject DMB-3115 Unknown 45 mg Subcutaneous
Subject DMB-3115 Unknown 90 mg Subcutaneous
Comparator Ustekinumab Monoclonal antibody 45 mg Subcutaneous
Comparator Ustekinumab Monoclonal antibody 90 mg Subcutaneous

Indications

psoriasis